This document summarizes guidelines from the Brain Trauma Foundation (BTF) for the management of traumatic brain injury (TBI). It provides indications and recommendations for surgery on various brain injuries like epidural hematomas, subdural hematomas, and depressed skull fractures based on factors like volume and Glasgow Coma Scale. It also outlines Level I-III evidence for treatments, monitoring thresholds, and recommendations regarding intracranial pressure, cerebral perfusion pressure, seizures and other topics.
Short description about awake craniotomy, its indications, contraindications, complications,various techniques of providing awake craniotomy and drugs used.
This presentation looks at intraoperative monitoring of auditory evoked potential, somato sensory evoked potential and motor evoked potential, procedure, pitfalls and utility.
Scalp block is simple and easy to perform. It has the advantages of minimizing cardiovascular effects and decreasing intraoperative analgesia requirements.
New GCS, the GCS-P was adopted in 2018 by the same person who proposed GCS. It gives better prognosticate outcomes compared to GCS.
Short description about awake craniotomy, its indications, contraindications, complications,various techniques of providing awake craniotomy and drugs used.
This presentation looks at intraoperative monitoring of auditory evoked potential, somato sensory evoked potential and motor evoked potential, procedure, pitfalls and utility.
Scalp block is simple and easy to perform. It has the advantages of minimizing cardiovascular effects and decreasing intraoperative analgesia requirements.
New GCS, the GCS-P was adopted in 2018 by the same person who proposed GCS. It gives better prognosticate outcomes compared to GCS.
BCC4: Michael Parr on ICU - Surviving Trauma GuidelinesSMACC Conference
Michael Parr, director of Liverpool ICU in Australia, speaks about "Surviving Trauma Guidelines". He does so through the use of an interesting case of a patient admitted to ICU following a MVA. This educational podcast was recorded at BCC4.
PCI is one of the most common procedures in the US, and remain a cornerstone in the management of ischemic heart disease.
Historically, a large proportion of PCI procedures were performed during inpatient hospitalization, allowing for a significant amount of time for monitoring postprocedure to ensure procedural success & identify bleeding or vascular complications, as well as for initiating secondary prevention.
However, technological pharmacological and procedural innovations, as well as payer expectations and cost considerations, have led to a shorter length of stay postprocedure and obviate hospital admission.
Most non-acute MI PCIs performed in the US now are performed under an outpatient designation.
PPT on all important trials of traumatic brain injury. - includes design, setting, statistical analysis,outcome, strength, limitations, conclusion#DECRA#RESCUEicp#BEST TRIP#CRASH1#CRASH3#SAFE TBI#EUROTHERM3939#POLAR TRIAL
Also includes trial related BTF guidelines
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
2. History : BTF
• 1986
• Dr Jam Ghajar
• HQ : Campbell, California
• Guidelines and Research fellowships in TBI
• Current is 4th Edition : 2016
• Living Guideline Model
3. Methods
• Systemic review
Class 1: Good quality RCT
Class 2: Mod RCT , Good Cohort / CCS
Class 3: low RCT, mod – low Cohort / CCS
• Synthesis of evidence
• Derivation of recommendation
4. Level of Evidence
LEVEL I (Standard)
• Prospective, Randomized, Controlled Trials
LEVEL II (Guideline)
• A: obtained from well-designed controlled trials without
randomization
• B: obtained from well-designed cohort or case-control
analytic studies, preferably from more than one center or
research group
LEVEL III (Optional)
• Case Series
• Case Reports
• Expert Opinion
5. Overview
• Indications for Surgery
• Treatment recommendation
• Monitoring recommendation
• Threshold recommendation
6. Epidural Hematoma
Indications
• Volume greater than 30cc should be evacuated
regardless of GCS
• Volume less than 30cc/less than 15mm
thickness/less than 5mm midline shift/GCS
greater than 8 may be managed non-operatively
Timing
• Any patient with acute EDH/GCS<9/anisocoria
should undergo operation “as soon as possible”
9. Subdural Hematoma
Indications
• SDH with thickness > 10mm/midline shift > 5mm should be
evacuated regardless of GCS
• Patients with acute SDH and GCS < 9 should have ICP
monitoring
• SDH with thickness < 10mm or < 5mm midline shift should
be evacuated if GCS drops 2 or more points from injury to
admission, pupillary function is abnormal, or ICP> 20 mm
Hg
Methods
• Craniotomy with or without bone flap removal/duroplasty
10.
11. Traumatic Parenchymal Lesions
Indications
• Parenchymal mass lesion with referable neurologic
deterioration, medically refractory intracranial hypertension
or signs of mass effect on CT should be evacuated
• Patients with GCS 6-8, with frontal or temporal lesion volume
> 20cc with midline shift >5mm or cisternal compression, or
any lesion volume > 50cc should be evacuated
• Parenchymal mass lesions without clinical neurologic
compromise, with no signs of mass effect and with controlled
ICP can be treated non-operatively
12. Posterior Fossa Mass Lesions
Indications
• Patients with mass effect on CT or neurologic
dysfunction or deterioration referable to a lesion
should undergo evacuation; “mass effect” is defined as
distortion of the 4th ventricle, effacement of basilar
cisterns or obstructive hydrocephalus
• Patients without mass effect of neurologic dysfunction
may be treated non-operatively
Methods
• Suboccipital craniectomy is the predominant method
reported and is therefore recommended
13. Depressed Cranial Fractures
Indications
• Open fractures with depression greater than the
thickness of the skull should be treated surgically to
prevent infection
• Open depressed skull fractures may be treated
non-operatively provided there is no evidence of
dural penetration, intraparenchymal hematoma,
depression > 1 cm, frontal sinus involvement, gross
cosmetic deformity, wound infection,
pneumocephalus, or gross wound contamination
• Closed depressed skull fractures may be treated
non-operatively
14. Methods
• Elevation and debridement is recommended
• Primary bone fragment replacement is an
option in the absence of wound infection at
the time of surgery
• All management options for open depressed
fractures should include antibiotics
16. DECOMPRESSIVE CRANIECTOMY
• There was insufficient evidence to support a
Level I recommendation for this topic.
• Level IIA
-Bifrontal DC is not recommended to improve
outcomes
-A large frontotemporoparietal DC (12 x 15 cm or
15 cm diameter) is recommended over a small
frontotemporoparietal DC
• RESCUEicp trial
17.
18.
19.
20. PROPHYLACTIC HYPOTHERMIA
• No Level I / II A
• LEVEL II B: Early (within 2.5 hours), short-term
(48 hours post-injury) prophylactic
hypothermia is not recommended to improve
outcomes in patients with diffuse injury.
21. HYPEROSMOLAR THERAPY
• LEVEL I, II, AND III: Although hyperosmolar
therapy may lower intracranial pressure, there
was insufficient evidence about effects on
clinical outcomes to support a specific
recommendation, or to support use of any
specific hyperosmolar agent, for patients with
severe traumatic brain injury.
22.
23. CEREBROSPINAL FLUID DRAINAGE
• There was insufficient evidence to support a Level I
or II recommendation for this topic.
LEVEL III
• An EVD system zeroed at the midbrain with
continuous drainage of CSF may be considered to
lower ICP burden more effectively than
intermittent use.
• Use of CSF drainage to lower ICP in patients with an
initial Glasgow Coma Scale (GCS) <6 during the first
12 hours after injury may be considered
24. VENTILATION THERAPIES
• There was insufficient evidence to support a
Level I or II A recommendation for this topic
LEVEL II B
• Prolonged prophylactic hyperventilation with
partial pressure of carbon dioxide in arterial
blood (PaCO2) of 25 mm Hg or less is not
recommended.
25. ANESTHETICS, ANALGESICS, AND
SEDATIVES
LEVEL II B
• Administration of barbiturates to induce burst suppression
measured by EEG as prophylaxis against the development
of intracranial hypertension is not recommended.
• High-dose barbiturate administration is recommended to
control elevated ICP refractory to maximum standard
medical and surgical treatment. Hemodynamic stability is
essential before and during barbiturate therapy.
• Although propofol is recommended for the control of ICP, it
is not recommended for improvement in mortality or 6-
month outcomes
26. STEROIDS
• LEVEL I: The use of steroids is not
recommended for improving outcome or
reducing ICP. In patients with severe TBI, high-
dose methylprednisolone was associated with
increased mortality and is contraindicated.
27.
28.
29. NUTRITION
• LEVEL II A: Feeding patients to attain basal
caloric replacement at least by the 5th day and
at most by the 7th day post-injury is
recommended to decrease mortality.
• LEVEL II B: Transgastric jejunal feeding is
recommended to reduce the incidence of
ventilator-associated pneumonia.
30. INFECTION PROPHYLAXIS
• LEVEL II A: Early tracheostomy is recommended
to reduce mechanical ventilation days when the
overall benefit is felt to outweigh the
complications associated with such a
procedure. However, there is no evidence that
early tracheostomy reduces mortality or the
rate of nosocomial pneumonia.
• The use of povidone-iodine (PI) oral care is not
recommended
• LEVEL III: Antimicrobial-impregnated catheters
may be considered to prevent catheter-related
infections during external ventricular drainage.
31. DEEP VEIN THROMBOSIS
PROPHYLAXIS
• LEVEL III: Low molecular weight heparin (LMWH) or
low-dose unfractioned heparin may be used in
combination with mechanical prophylaxis. However,
there is an increased risk for expansion of intracranial
hemorrhage.
• In addition to compression stockings, pharmacologic
prophylaxis may be considered if the brain injury is
stable and the benefit is considered to outweigh the
risk of increased intracranial hemorrhage. There is
insufficient evidence to support recommendations
regarding the preferred agent, dose, or timing of
pharmacologic prophylaxis for deep vein thrombosis.
32. SEIZURE PROPHYLAXIS
• LEVEL II A: Prophylactic use of phenytoin or valproate
is not recommended for preventing late post traumatic
seizures (PTS).
• Phenytoin is recommended to decrease the incidence
of early PTS (within 7 days of injury), when the overall
benefit is felt to outweigh the complications associated
with such treatment. However, early PTS have not been
associated with worse outcomes.
• At the present time there is insufficient evidence to
recommend levetiracetam over phenytoin regarding
efficacy in preventing early post-traumatic seizures and
toxicity.
33. • The risk factors for early PTS include:
Glasgow Coma Scale (GCS) score of ≤10;
immediate seizures; post-traumatic amnesia
lasting longer than 30 minutes; linear or
depressed skull fracture; penetrating head
injury; subdural, epidural, or intracerebral
hematoma; cortical contusion; age ≤65
years; or chronic alcoholism.
35. INTRACRANIAL PRESSURE
MONITORING
• LEVEL II B: Management of severe TBI patients
using information from ICP monitoring is
recommended to reduce in-hospital and 2-
week post-injury mortality.
36. CEREBRAL PERFUSION PRESSURE
MONITORING
• LEVEL II B: Management of severe TBI patients
using guidelines-based recommendations for
CPP monitoring is recommended to decrease
2-week mortality.
•
37. ADVANCED CEREBRAL MONITORING
• LEVEL III: Jugular bulb monitoring of
arteriovenous oxygen content difference
(AVDO2), as a source of information for
management decisions, may be considered to
reduce mortality and improve outcomes at 3
and 6 months post-injury.
39. Blood Pressure Thresholds
• LEVEL III: Maintaining SBP at ≥100 mm Hg for
patients 50 to 69 years old or at ≥110 mm Hg
or above for patients 15 to 49 or over 70 years
old may be considered to decrease mortality
and improve outcomes.
40. INTRACRANIAL PRESSURE
THRESHOLDS
• LEVEL II B: Treating ICP above 22 mm Hg is
recommended because values above this level
are associated with increased mortality.
• LEVEL III: A combination of ICP values and
clinical and brain CT findings may be used to
make management decisions.
41. CEREBRAL PERFUSION PRESSURE
THRESHOLDS
• LEVEL II B: The recommended target cerebral
perfusion pressure (CPP) value for survival and
favorable outcomes is between 60 and 70 mm
Hg. Whether 60 or 70 mm Hg is the minimum
optimal CPP threshold is unclear and may depend
upon the patient’s autoregulatory status.
• LEVEL III: Avoiding aggressive attempts to
maintain CPP above 70 mm Hg with fluids and
pressors may be considered because of the risk of
adult respiratory failure.
42. ADVANCED CEREBRAL MONITORING
THRESHOLDS
• LEVEL III: Jugular venous saturation of <50%
may be a threshold to avoid in order to reduce
mortality and improve outcomes.